SCHEMBL23743045

SCHEMBL23743045

c1cn(C2CCC2)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27350163 0.98 EPHX1 (0.37)
SCHEMBL17675657 0.95 EPHX1 (0.38)
SCHEMBL20032245 0.93 EPHX1 (0.37)
SCHEMBL20031997 0.93 EPHX1 (0.37)
SCHEMBL20031998 0.93 EPHX1 (0.37)
SCHEMBL5683395 0.93 EPHX1 (0.37)
SCHEMBL12984443 0.90
SCHEMBL23697388 0.90 EPHX1 (0.34)
SCHEMBL19179014 0.82 EPHX1 (0.33)
SCHEMBL14704905 0.82 HCAR2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 US disclosed
US-20230321067-A1 DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2023-10-12 US disclosed
WO-2021158412-A1 ELECTROCHEMICALLY-CLEAVABLE LINKERS MICROSOFT TECHNOLOGY LICENSING, LLC (US) 2021-08-12 WO disclosed